Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia
- PMID: 30621854
- DOI: 10.1016/j.chest.2018.10.014
Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia
Abstract
Background: In culture-positive nosocomial pneumonia, de-escalation (DE) from broad-spectrum empirical antimicrobials to narrower-spectrum agents has shown to decrease broad-spectrum antibiotic use without compromising patient outcomes. However, uncertainty exists regarding the safety of anti-methicillin-resistant Staphylococcus aureus (MRSA) agent DE in culture-negative nosocomial pneumonia. This study aimed to determine if anti-MRSA agent DE in culture-negative nosocomial pneumonia affects 28-day and hospital mortality, ICU and hospital length of stay (LOS), treatment failure, and safety.
Methods: This single-center retrospective cohort study included adult patients admitted from 2012 to 2017 with nosocomial pneumonia and a negative respiratory culture. DE was defined as anti-MRSA agent discontinuation within 4 days of initiation. Secondary outcomes included hospital mortality, hospital and ICU LOS, treatment failure, and occurrence of acute kidney injury (AKI).
Results: Of 279 patients included, 92 were in the DE group and 187 were in the no DE (NDE) group. Patients who were not de-escalated received 5 more days of MRSA coverage than patients who were de-escalated; however, there was no difference in 28-day mortality (NDE group, 28% vs DE group, 23%; difference, -5.5%; 95% CI, -16.1 to 6.5). Patients who were de-escalated had shorter hospital (DE group, 15 days vs NDE group, 20 days; difference, 3.2 days; 95% CI, 0.1-6.4) and ICU (DE group, 10 days vs NDE group, 13 days; difference, 2.2 days; 95% CI, -0.3 to 4.9) LOSs after the index date. The incidence of AKI was significantly higher in patients who were not de-escalated (DE group, 36% vs NDE group, 50%; difference, -13.8%; 95% CI, -26.9 to -0.4).
Conclusions: Although anti-MRSA agent DE in culture-negative nosocomial pneumonia did not affect 28-day mortality, it was associated with a shorter hospital LOS and lower incidence of AKI.
Keywords: de-escalation; methicillin-resistant Staphylococcus aureus; pneumonia.
Copyright © 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction assay in critically ill patients with nosocomial pneumonia.J Crit Care. 2017 Apr;38:168-171. doi: 10.1016/j.jcrc.2016.11.008. Epub 2016 Nov 15. J Crit Care. 2017. PMID: 27918901
-
The Daniel K. Inouye College of Pharmacy Scripts: The Effects of Vancomycin Use and De-escalation in Patients Hospitalized with Pneumonia.Hawaii J Med Public Health. 2018 Oct;77(10):261-267. Hawaii J Med Public Health. 2018. PMID: 30324005 Free PMC article.
-
Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: A retrospective cohort analysis: Effectiveness of linezolid in the elderly.Am J Emerg Med. 2017 Feb;35(2):245-248. doi: 10.1016/j.ajem.2016.10.058. Epub 2016 Oct 29. Am J Emerg Med. 2017. PMID: 27832976
-
Safety of De-Escalating Empiric Antimicrobial Agents in Trauma Patients with Indigenous Oral Flora Ventilator-Associated Pneumonia.Surg Infect (Larchmt). 2022 Aug;23(6):597-603. doi: 10.1089/sur.2022.126. Surg Infect (Larchmt). 2022. PMID: 35917387 Review.
-
Treatment options for nosocomial pneumonia due to MRSA.J Infect. 2009 Sep;59 Suppl 1:S25-31. doi: 10.1016/S0163-4453(09)60005-0. J Infect. 2009. PMID: 19766886 Review.
Cited by
-
Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?Microorganisms. 2023 Sep 4;11(9):2231. doi: 10.3390/microorganisms11092231. Microorganisms. 2023. PMID: 37764075 Free PMC article. Review.
-
The impact of antimicrobial de-escalation therapy in culture-negative pneumonia: a systematic review and meta-analysis.Korean J Intern Med. 2023 Sep;38(5):704-713. doi: 10.3904/kjim.2023.115. Epub 2023 Aug 17. Korean J Intern Med. 2023. PMID: 37586813 Free PMC article.
-
Effect of antimicrobial de-escalation strategy on 14-day mortality among intensive care unit patients: a retrospective propensity score-matched cohort study with inverse probability-of-treatment weighting.BMC Infect Dis. 2023 Aug 4;23(1):508. doi: 10.1186/s12879-023-08491-7. BMC Infect Dis. 2023. PMID: 37537526 Free PMC article.
-
Performance of Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction Nasal Screening for Ruling Out MRSA Pneumonia in Hospitalized, Immunocompromised Patients.J Pharm Technol. 2023 Aug;39(4):191-194. doi: 10.1177/87551225231182876. Epub 2023 Jun 27. J Pharm Technol. 2023. PMID: 37529151 Free PMC article.
-
Antibiotic stewardship in the ICU: time to shift into overdrive.Ann Intensive Care. 2023 May 6;13(1):39. doi: 10.1186/s13613-023-01134-9. Ann Intensive Care. 2023. PMID: 37148398 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
